Imaging swallowing and speech muscles in people with inclusion body myositis
Tests ultrasound and MRI to assess swallowing muscles in adults with inclusion body myositis.
Plain-language title generated from the registry record
Registry title: Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
Key facts
- Where
- Baltimore, United StatesSee the site
Where in United States
- The Johns Hopkins HospitalBaltimore, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Johns Hopkins University
- Trial code
- NCT07823101
- Record updated
- 28 October 2026
- Original description
This study will evaluate whether neuromuscular ultrasound and MRI can be used as imaging markers of bulbar involvement and swallowing dysfunction in individuals with inclusion body myositis (IBM). Researchers will compare imaging and clinical findings in participants with IBM with those in participants with other myopathies, ALS, PLS, and healthy volunteers.Read full original descriptionShow less
Advancing Bulbar Assessment in Inclusion Body Myositis Through a Multimodal Imaging Approach
This study will evaluate whether neuromuscular ultrasound and MRI can be used as imaging markers of bulbar involvement and swallowing dysfunction in individuals with inclusion body myositis (IBM). Researchers will compare imaging and clinical findings in participants with IBM with those in participants with other myopathies, ALS, PLS, and healthy volunteers.
The study is a one-time visit. Study procedures may include neurological assessments, swallowing questionnaires, tongue strength testing, neuromuscular ultrasound, and MRI. The goal is to identify more sensitive and objective ways to assess bulbar dysfunction biomarkers.
Inclusion: Participants must have a confirmed diagnosis of inclusion body myositis (IBM), amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS), or myopathy in accordance with the respective diagnostic criteria; Participants with disease must have clinically relevant laboratory testing for disease biomarkers (e.g., Creatine Kinase (CK), Comprehensive Metabolic Panel (CMP), Complete Blood Count (CBC)) within the last 12 months; Participants must be able to remain supine for 30 minutes or longer and cannot have significant breathing difficulties; Healthy controls must not have any neuromuscular disease.
Exclusion: Patients with IBM, ALS, or myopathy who have another known neuromuscular condition with known bulbar involvement; Medical history or clinically significant physical examination or laboratory results that, in the opinion of the investigator, would render the participant unsuitable for the study; Unable or unwilling to provide written informed consent; Participants who are unlikely to comply with the study protocol or, in the opinion of the investigator, would not be a suitable candidate for participation in the study; Any patient who has undergone a procedure for dysphagia, including myotomy, dilatation, or Botox.